Abstract ISI
JOURNAL OF CLINICAL ONCOLOGY  (2019)

Thirty-month follow-up of the phase III CheckMate 214 trial of first-line nivolumab plus ipilimumab (N plus I) or sunitinib (S) in patients (pts) with advanced renal cell carcinoma (aRCC).

Tannir, NM; Frontera, OA; Hammers, HJ; Carducci, MA; McDermott, DF; Salman, P; Escudier, B; Beuselinck, B; Amin, A; Porta, C; George, S; Bracarda, S; Tykodi, SS; Powles, T; Rini, BI; et. al.